Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

被引：0
作者：
Kim Dalziel
Ali Round
Ruth Garside
Ken Stein
机构：
[1] Peninsula Medical School,Peninsula Technology Assessment Group
[2] Universities of Exeter and Plymouth,Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Imatinib; Bone Marrow Transplantation; Chronic Myeloid Leukaemia; Blast Crisis; Cytogenetic Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-α or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.
引用
收藏
页码：515 / 526
页数：11
相关论文
共 50 条
  • [31] An extremely delayed cytogenetic response to interferon-α in a patient with chronic myeloid leukaemia
    AJ Whiteway
    CDL Reid
    NCP Cross
    Leukemia, 1997, 11 : 614 - 616
  • [32] Expression of interferon regulatory factor (IRF) genes and response to interferon-α in chronic myeloid leukaemia
    A Hochhaus
    XH Yan
    A Willer
    R Hehlmann
    MY Gordon
    JM Goldman
    JV Melo
    Leukemia, 1997, 11 : 933 - 939
  • [33] Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
    Chen, Teng-Chou
    Chen, Li-Chia
    Huang, Yaw-Bin
    Chang, Chao-Sung
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (01) : 172 - 181
  • [34] Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
    Teng-Chou Chen
    Li-Chia Chen
    Yaw-Bin Huang
    Chao-Sung Chang
    International Journal of Clinical Pharmacy, 2014, 36 : 172 - 181
  • [35] Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    A Hochhaus
    S G O'Brien
    F Guilhot
    B J Druker
    S Branford
    L Foroni
    J M Goldman
    M C Müller
    J P Radich
    M Rudoltz
    M Mone
    I Gathmann
    T P Hughes
    R A Larson
    Leukemia, 2009, 23 : 1054 - 1061
  • [36] Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    Hochhaus, A.
    O'Brien, S. G.
    Guilhot, F.
    Druker, B. J.
    Branford, S.
    Foroni, L.
    Goldman, J. M.
    Mueller, M. C.
    Radich, J. P.
    Rudoltz, M.
    Mone, M.
    Gathmann, I.
    Hughes, T. P.
    Larson, R. A.
    LEUKEMIA, 2009, 23 (06) : 1054 - 1061
  • [37] New strategies for the first-line treatment of chronic myeloid leukemia: Can resistance be avoided?
    Snead, Jennifer L.
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 : S107 - S117
  • [38] BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
    Hughes, T. P.
    Saglio, G.
    Quintas-Cardama, A.
    Mauro, M. J.
    Kim, D-W
    Lipton, J. H.
    Bradley-Garelik, M. B.
    Ukropec, J.
    Hochhaus, A.
    LEUKEMIA, 2015, 29 (09) : 1832 - 1838
  • [39] Successful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon-α: A case report
    Jia, Meng-Xiao
    Di, Da-Lin
    Liu, Zhen-Zhen
    Wang, Hai-Ying
    Chen, Lei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2025, 29 (03)
  • [40] The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia
    Andrews, Claire N.
    Lipton, Jeffrey
    LANCET HAEMATOLOGY, 2019, 6 (08): : E385 - E386
12345